Patient social function and quality of life in schizophrenia: focus on paliperidone palmitate
The long-term outcomes of treatment with new selective antipsychotic for patients with schizophrenia have been discussed. Using the example of patients treated with “Xeplion” for secondary prevention of worsening symptoms of the disorder and changing in patient social functionality are in the focus....
Saved in:
| Main Author: | E. V. Grigorieva |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Federal State Budget Scientific Institution National Medical Research Center for Psychiatry and Neurology n.a. V.M. Bekhterev Ministry of Health of the Russian Federation
2018-07-01
|
| Series: | Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева |
| Subjects: | |
| Online Access: | https://www.bekhterevreview.com/jour/article/view/64 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical effectiveness of paliperidone palmitate 3‐monthly and 1‐monthly as monotherapy in patients with schizophrenia: A retrospective cohort study based on the Medicaid claims database
by: Chih‐Lin Chiang, et al.
Published: (2024-12-01) -
Population Pharmacokinetics of Risperidone and Paliperidone in Schizophrenia: A Systematic Review
by: Ana Carrascosa-Arteaga, et al.
Published: (2025-05-01) -
Efficacy and safety of paliperidone palmitate 1-month formulation (PP1M) for schizophrenia in southwestern China
by: Lian Gou, et al.
Published: (2025-04-01) -
Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
by: Li H, et al.
Published: (2015-12-01) -
Long-Term Symptomatic and Functional Remission with Paliperidone Palmitate 6-Monthly Treatment in Schizophrenia: A 3-Year Post-Hoc Analysis
by: Hamilton JM, et al.
Published: (2025-06-01)